Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma

BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for ∼5% of all thyroid malignancies. To date, surgery is the first-line therapy with curative intention. However, for advanced MTC, conventional chemotherapeutic agents do not provide convincing results. Therefore, the identification of biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Thomas A, Tamkan-Ölcek, Yasemin, Dizdar, Levent, Riemer, Jasmin C, Wolf, Achim, Cupisti, Kenko, Verde, Pablo E, Knoefel, Wolfram T, Krieg, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815780/
https://www.ncbi.nlm.nih.gov/pubmed/26882066
http://dx.doi.org/10.1038/bjc.2016.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815780/
https://www.ncbi.nlm.nih.gov/pubmed/26882066
http://dx.doi.org/10.1038/bjc.2016.5

Ejemplares similares